8-K

                       SECURITIES AND EXCHANGE COMMISSION

                            WASHINGTON, D. C.  20549

                                  ____________



                                    FORM 8-K



                                 CURRENT REPORT



                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                          DATE OF REPORT: JULY 18, 2000
                        (Date of earliest event reported)


                              INCYTE GENOMICS, INC.
                     (FORMERLY INCYTE PHARMACEUTICALS, INC.)
             (Exact name of registrant as specified in its charter)


               DELAWARE                      0-27488         94-3136539
         (State or other jurisdiction      (Commission     (IRS Employer
           of incorporation)               File Number)    Identification
                                                                No.)


           3160 PORTER DRIVE, PALO ALTO, CALIFORNIA              94304
           (Address of principal executive offices)             (Zip Code)


       Registrant's telephone number, including area code:  (650) 855-0555



Item  5.     Other  Events.
             -------------

     Attached hereto as Exhibit 99.1 and incorporated by reference herein is the
press  release  dated  July 18, 2000 announcing that Incyte's board of directors
have  approved a two-for-one stock split in the form of a stock dividend. Incyte
stockholders  of  record at the close of business on August 7, 2000 will receive
one  additional  share  for  each  share  of  common stock held at the time. The
additional  shares  will  be  distributed to eligible stockholders on August 31,
2000.

Item  7.  Financial  Statements  and  Exhibits.
          ------------------------------------

     (c)     Exhibits

99.1     Press  release  dated  July  18,  2000.



                                    SIGNATURE


     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  hereunto  duly  authorized.


                                 Dated:  July  18,  2000

                                 INCYTE  GENOMICS,  INC.

                                 By    /s/  John  M.  Vuko
                                       -------------------
                                       Name:  John  M.  Vuko
                                       Title: Executive  Vice  President  and
                                       Chief  Financial  Officer

EX-99.1

EXHIBIT  99.1
- -------------



FOR  IMMEDIATE  RELEASE
- -----------------------

INCYTE
John  Vuko
Chief  Financial  Officer
(650)  845-4106


                      INCYTE ANNOUNCES 2-FOR-1 STOCK SPLIT

PALO  ALTO,  CALIFORNIA,  JULY 18, 2000 -- Incyte Genomics, Inc. (Nasdaq: INCY),
today  announced  that  its  board of directors has approved a two-for-one stock
split  in  the  form  of a stock dividend.  Incyte stockholders of record at the
close  of  business on August 7, 2000 will receive one additional share for each
share  of  common  stock  held  at  that  time.  The  additional  shares will be
distributed  to  eligible stockholders on August 31, 2000.  The stock split will
increase  the number of shares of common stock outstanding from approximately 32
million  to  approximately  64  million.

Incyte  Genomics,  Inc.  is  the  leading  provider of an integrated platform of
genomic technologies designed to aid in the understanding of the molecular basis
of  disease.  Incyte  develops  and  markets  genomic  databases and partnership
programs,  genomic  data  management  software, microarray-based gene expression
services,  related reagents and services.  These products, programs and services
assist  pharmaceutical  and  biotechnology  researchers  with all phases of drug
discovery  and  development  including  gene  discovery,  understanding  disease
pathways,  identifying  new disease targets and the discovery and correlation of
gene  sequence  variation  to disease.  For more information, visit Incyte's web
site  at  www.incyte.com.

Except for the historical information contained herein, the matters set forth in
this  press  release,  are  forward-looking statements within the meaning of the
"safe  harbor"  provisions  of  the  Private Securities Litigation Reform Act of
1995.  These  forward-looking  statements are subject to risks and uncertainties
that may cause actual results to differ materially.  For a discussion of factors
that  may  cause  results  to  differ,  see  Incyte's SEC reports, including its
Quarterly  Report  on  Form  10-Q  for the quarter ended March 31, 2000.  Incyte
disclaims  any  intent or obligation to update these forward-looking statements.

                                       ###